Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP2013 vs rituximab in rheumatoid arthritis refractory to DMARDs and anti-TNF therapies
2010-021184-32Phase 2Completed
- Sponsor
- Hexal AG
- Start
- Aug 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rituximab in Refractory rheumatoid arthritis (RRA) (2 arms), sponsored by Hexal AG. Primary endpoint: Primary pharmacokinetic comparison of GP2013 vs rituximab. Started Aug 2010; status: completed.
02
Drugs
rituximab
03
Conditions
Refractory rheumatoid arthritis (RRA)
Beyond the preview
Go deeper on 2010-021184-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021184-32.